Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2014, Pages 590-597

  Langer, Florian ^a   Ruf, Wolfram ^b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Phosphatidylserine; Protein disulfide isomerase; Thioldisulfide exchange; Thrombosis; Tissue factor

Indexed keywords

ADENOSINE TRIPHOSPHATE; DISULFIDE; PHOSPHATIDYLSERINE; PROTEIN DISULFIDE ISOMERASE; PURINERGIC P2X7 RECEPTOR; THIOL; THROMBIN; THROMBOPLASTIN; CARBOXYLYASE; LYMPHOCYTE ANTIBODY; PHOSPHATIDYLSERINE DECARBOXYLASE;

ARTICLE; BLOOD CLOTTING; BONE MARROW CELL; CELL ACTIVATION; CELL MEMBRANE; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; INFLAMMATION; MEMBRANE MICROPARTICLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SMOOTH MUSCLE FIBER; THROMBOSIS; ANIMAL; BLOOD; COMPLEMENT ACTIVATION; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM;

ANIMALS; ANTILYMPHOCYTE SERUM; BLOOD COAGULATION; CARBOXY-LYASES; COMPLEMENT ACTIVATION; DRUG SYNERGISM; HUMANS; INFLAMMATION; MYELOID CELLS; MYOCYTES, SMOOTH MUSCLE; PROTEIN DISULFIDE-ISOMERASES; RECEPTORS, PURINERGIC P2X7; THROMBOPLASTIN; THROMBOSIS;

EID: 84897497741     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-09-0802     Document Type: Article

References (97)

1. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
2. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006; 32: 5-10.
3. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097.
4. Owens AP 3rd, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep 2012; 14: 394-401.
5. Lechner D, Weltermann A. Circulating tissue factor-exposing microparticles. Thromb Res 2008; 122 (Suppl 1): S47-S54.
6. Lippi G, Cervellin G. Disseminated intravascular coagulation in trauma injuries. Semin Thromb Hemost 2010; 36: 378-387.
7. Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost 2012; 38: 506-514.
8. Langer F, Bokemeyer C. Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor. Hamostaseologie 2012; 32: 95-104.
9. Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost 2009; 102: 916-924.
10. Pawlinski R, Wang JG, Owens AP 3rd, et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 2010; 116: 806-814.
11. Baroni M, Pizzirani C, Pinotti M, et al. Stimulation of P2 (P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles. FASEB J 2007; 21: 1926-1933.
12. Aharon A, Tamari T, Brenner B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost 2008; 100: 878-885.
13. Furlan-Freguia C, Marchese P, Gruber A, et al. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 2011; 121: 2932-2944.
14. Sovershaev MA, Egorina EM, Osterud B, et al. Evidence for direct transfer of tissue factor from monocytes to platelets in whole blood. Blood Coagul Fibrinolysis 2012; 23: 345-350.
15. Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
16. Zhou J, May L, Liao P, et al. Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol 2009; 29: 863-869.
17. Darbousset R, Thomas GM, Mezouar S, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012; 120: 2133-2143.
18. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209: 819-835.
19. Schulz C, Engelmann B, Massberg S. Crossroads of coagulation and innate immunity: the case of deep vein thrombosis. J Thromb Haemost 2013; 11 (Suppl 1): 233-241.
20. Tanaka M, Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemic cells. Leuk Res 1993; 17: 103-111.
21. Drake TA, Ruf W, Morrissey JH, et al. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-395.
22. Langer F, Amirkhosravi A, Loges S, et al. An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thromb Haemost 2004; 92: 1136-1146.
23. Takemori N, Hirai K, Onodera R, et al. Disseminated intravascular coagulation in a patient with acute myeloid leukemia. Ultrastructural evidence of hypercoagulation in bone marrow. Am J Clin Pathol 1993; 99: 695-701.
24. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89: 3270-3276.
25. Broze GJ Jr. Binding of human factor VII and VIIa to monocytes. J Clin Invest 1982; 70: 526-535.
26. Fair DS, MacDonald MJ. Cooperative interaction between factor VII and cell surface-expressed tissue factor. J Biol Chem 1987; 262: 11692-11698.
27. Sakai T, Lund-Hansen T, Paborsky L, et al. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsic pathway of blood coagulation. J Biol Chem 1989; 264: 9980-9988.
28. Le DT, Rapaport SI, Rao LV. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267: 15447-15454.
29. Sorensen BB, Persson E, Freskgârd PO, et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-11868.
30. Pendurthi UR, Allen KE, Ezban M, et al. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction. J Biol Chem 2000; 275: 14632-14641.
31. Rao LV, Pendurthi UR. Regulation of tissue factor coagulant activity on cell surfaces. J Thromb Haemost 2012; 10: 2242-2253.
32. Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost 2013; 11 (Suppl 1): 277-284.
33. Kothari H, Pendurthi UR, Rao LV. Analysis of tissue factor expression in various cell model systems: cryptic vs. active. J Thromb Haemost 2013; 11: 1353-1363.
34. Ahamed J, Versteeg HH, Kerver M, et al. Disulfide isomerisation switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 2006; 103: 13932-13937.
35. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-6999.
36. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-461.
37. Wolberg AS, Monroe DM, Roberts HR, et al. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserinedependent and-independent mechanisms. Blood Coagul Fibrinolysis 1999; 10: 201-210.
38. Neuenschwander PF, Bianco-Fisher E, Rezaie AR, et al. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-13993.
39. Tavoosi N, Davis-Harrison RL, Pogorelov TV, et al. Molecular determinants of phospholipid synergy in blood clotting. J Biol Chem 2011; 286: 23247-23253.
40. Henriksson CE, Klingenberg O, Ovstebø R, et al. Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 2005; 94: 1236-1244.
41. Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 1990; 76: 361-367.
42. Boles JC, Williams JC, Hollingsworth RM, et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res 2012; 129: 197-203.
43. Dasgupta SK, Guchhait P, Thiagarajan P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl Res 2006; 148: 19-25.
44. Shi J, Shi Y, Waehrens LN, et al. Lactadherin detects early phosphatidylserine exposure on immortalized leukemia cells undergoing programmed cell death. Cytometry A 2006; 69: 1193-1201.
45. Wolberg AS, Kon RH, Monroe DM, et al. Deencryption of cellular tissue factor is independent of its cytoplasmic domain. Biochem Biophys Res Commun 2000; 272: 332-336.
46. Chen VM, Ahamed J, Versteeg HH, et al. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 12020-12028.
47. Le DT, Rapaport SI, Rao LV. Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. Thromb Haemost 1994; 72: 848-855.
48. Ruf W, Schullek JR, Stone MJ, et al. Mutational mapping of functional residues in tissue factor: identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. Biochemistry 1994; 33: 1565-1572.
49. Sen P, Neuenschwander PF, Pendurthi UR, et al. Analysis of factor VIIa binding to relipidated tissue factor by surface plasmon resonance. Blood Coagul Fibrinolysis 2010; 21: 376-379.
50. Ohkubo YZ, Morrissey JH, Tajkhorshid E. Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J Thromb Haemost 2010; 8: 1044-1053.
51. Ruf W, Miles DJ, Rehemtulla A, et al. Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem 1992; 267: 6375-6381.
52. Ruf W, Miles DJ, Rehemtulla A, et al. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267: 22206-22210.
53. Chen VM, Hogg PJ. Allosteric disulfide bonds in thrombosis and thrombolysis. J Thromb Haemost 2006; 4: 2533-2541.
54. Liang HP, Brophy TM, Hogg PJ. Redox properties of the tissue factor Cys186-Cys209 disulfide bond. Biochem J 2011; 437: 455-460.
55. Reinhardt C, von Brühl ML, Manukyan D, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118: 1110-1122.
56. Ruf W, Versteeg HH. Tissue factor mutated at the allosteric Cys186-Cys209 disulfide bond is severely impaired in decrypted procoagulant activity. Blood 2010; 116: 500-501.
57. van den Hengel LG, Kocatürk B, Reitsma PH, et al. Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor. Blood 2011; 118: 3446-3448.
58. van den Hengel LG, Osanto S, Reitsma PH, et al. Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide. Haematologica 2013; 98: 153-158.
59. Krudysz-Amblo J, Jennings ME 2nd, Knight T, et al. Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 2013; 1830: 3489-3496.
60. Kothari H, Nayak RC, Rao LV, et al. Cystine 186-cystine 209 disulfide bond is not essential for the procoagulant activity of tissue factor or for its de-encryption. Blood 2010; 115: 4273-4283.
61. Bach RR, Monroe D. What is wrong with the allosteric disulfide bond hypothesis? Arterioscler Thromb Vasc Biol 2009; 29: 1997-1998.
62. Banner DW, D'Arcy A, Chène C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-46.
63. Bajaj SP, Schmidt AE, Agah S, et al. High resolution structures of p-aminobenzamidine-and benzamidine-VIIa/soluble tissue factor: unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+, and Zn2+ sites in factor VIIa. J Biol Chem 2006; 281: 24873-24888.
64. Ruf W, Kelly CR, Schullek JR, et al. Energetic contributions and topographical organisation of ligand binding residues of tissue factor. Biochemistry 1995; 34: 6310-6315.
65. Gibbs C, McCurdy S, Leung L, et al. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994; 33: 14003-14010.
66. Ruf W, Kalnik MW, Lund-Hansen T, et al. Characterisation of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions. J Biol Chem 1991; 266: 15719-15725.
67. Huang M, Syed R, Stura EA, et al. The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TF-5G9 complex. J Mol Biol 1998; 275: 873-894.
68. Langer F, Spath B, Fischer C, et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood 2013; 121: 2324-2335.
69. Pendurthi UR, Ghosh S, Mandal SK, et al. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 2007; 110: 3900-3908.
70. Liang HP, Hogg PJ. Critical importance of the cell system when studying tissue factor de-encryption. Blood 2008; 112: 912-913.
71. Schwaller M, Wilkinson B, Gilbert HF. Reduction-reoxidation cycles contribute to catalysis of disulfide isomerisation by protein-disulfide isomerase. J Biol Chem 2003; 278: 7154-7159.
72. Lundström J, Holmgren A. Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. J Biol Chem 1990; 265: 9114-9120.
73. Chen K, Lin Y, Detwiler TC. Protein disulfide isomerase activity is released by activated platelets. Blood 1992; 79: 2226-2228.
74. Essex DW, Chen K, Swiatkowska M. Localisation of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 1995; 86: 2168-2173.
75. Popescu NI, Lupu C, Lupu F. Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure. Blood 2010; 116: 993-1001.
76. Jiang XM, Fitzgerald M, Grant CM, et al. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J Biol Chem 1999; 274: 2416-2423.
77. Ramachandran N, Root P, Jiang XM, et al. Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase. Proc Natl Acad Sci USA 2001; 98: 9539-9544.
78. Sliskovic I, Raturi A, Mutus B. Characterisation of the S-denitrosation activity of protein disulfide isomerase. J Biol Chem 2005; 280: 8733-8741.
79. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by proteindisulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007; 282: 25416-25424.
80. Raturi A, Ruf W. Effect of protein disulfide isomerase chaperone activity inhibition on tissue factor activity. J Thromb Haemost 2010; 8: 1863-1865.
81. Cho J, Furie BC, Coughlin SR, et al. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 2008; 118: 1123-1131.
82. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood 2010; 116: 4665-4674.
83. Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest 2012; 122: 2104-2113.
84. Cho J, Kennedy DR, Lin L, et al. Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins. Blood 2012; 120: 647-655.
85. Hahm E, Li J, Kim K, et al. Extracellular protein disulfide isomerase regulates ligand-binding activity of αMβ2 integrin and neutrophil recruitment during vascular inflammation. Blood 2013; 121: 3789-3800.
86. Kim K, Hahm E, Li J, et al. Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice. Blood 2013; 122: 1052-1061.
87. Jurk K, Lahav J, VAN Aken H, et al. Extracellular protein disulfide isomerase regulates feedback activation of platelet thrombin generation via modulation of coagulation factor binding. J Thromb Haemost 2011; 9: 2278-2290.
88. Wu Y, Ahmad SS, Zhou J, et al. The disulfide isomerase ERp57 mediates platelet aggregation, hemostasis, and thrombosis. Blood 2012; 119: 1737-1746.
89. King BC, Nowakowska J, Karsten CM, et al. Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces. J Immunol 2012; 188: 4103-4112.
90. Dorfleutner A, Hintermann E, Tarui T, et al. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 2004; 15: 4416-4425.
91. Wang P, Wu Y, Li X, et al. Thioredoxin and thioredoxin reductase control tissue factor activity by thiol redox-dependent mechanism. J Biol Chem 2013; 288: 3346-3358.
92. Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res 2003; 111: 235-238.
93. Weitz IC, Razavi P, Rochanda L, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res 2012; 130: 361-368.
94. Roth RI. Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin. Blood 1994; 83: 2860-2865.
95. Setty BN, Betal SG, Zhang J, et al. Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008; 6: 2202-2209.
96. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 2013; 122: 282-292.
97. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 2013; 162: 3-14.